IBR
Swiss GxP-compliant contract research organization (founded 1998) providing bioanalytical services across discovery, pre-clinical and clinical development. Core activities include development, validation and operation of immunoassays, cell-based bioassays, PK/TK and biomarker testing, lot release support and immunogenicity assessment under GLP/GMP/GCP and applicable regulatory guidance.
Industries
Nr. of Employees
small (1-50)
IBR
Lauchefeld 31, CH-9548 Matzingen, Switzerland
Patents
Products
Cell-based Assays
Assays using primary cells, transformed cell lines, reporter-gene systems, and 3D cell systems to evaluate biological activity and immune responses.
Cellular Immunology Services
In-vitro assays to assess immune cell phenotypes, functions, and effector mechanisms including ADCC, ADCP, CDC, and immune cell activation.
Gyrolab™ xPlore Immunoassay Platform
Automated microfluidic immunoassay system enabling high-throughput, nanoliter-scale sample analysis with broad dynamic range and reduced matrix effects.
Alpha Technology, TR-FRET, and TRF Detection Modes
Advanced fluorescence-based detection methods for biomolecular interactions and immunoassays using time-resolved and proximity-based energy transfer techniques.
Meso Scale Discovery (MSD) Immunoassay Platform
Electrochemiluminescence-based multiplex immunoassay system for sensitive detection of biomarkers in complex matrices.
Lot Release Testing Services
Bioanalytical testing of biologics, vaccines, and small molecules to support regulatory lot release and quality control.
Cell-based Assays
Assays using primary cells, transformed cell lines, reporter-gene systems, and 3D cell systems to evaluate biological activity and immune responses.
Cellular Immunology Services
In-vitro assays to assess immune cell phenotypes, functions, and effector mechanisms including ADCC, ADCP, CDC, and immune cell activation.
Gyrolab™ xPlore Immunoassay Platform
Automated microfluidic immunoassay system enabling high-throughput, nanoliter-scale sample analysis with broad dynamic range and reduced matrix effects.
Alpha Technology, TR-FRET, and TRF Detection Modes
Advanced fluorescence-based detection methods for biomolecular interactions and immunoassays using time-resolved and proximity-based energy transfer techniques.
Meso Scale Discovery (MSD) Immunoassay Platform
Electrochemiluminescence-based multiplex immunoassay system for sensitive detection of biomarkers in complex matrices.
Lot Release Testing Services
Bioanalytical testing of biologics, vaccines, and small molecules to support regulatory lot release and quality control.
Services
Tiered ADA testing (screening, confirmatory, neutralizing) including sample pre-treatment strategies and cell-based/non-cell-based neutralization assays for clinical sample analysis.
Independent lot release support for biologics, vaccines and small molecules including potency, protein analytics, physico‑chemical and stability-related tests performed under GMP requirements.
Custom potency assays, ADCC/ADCP/CDC, reporter-gene assays, whole blood and T‑cell cytotoxicity assays using primary cells, cell lines and 3D systems, with automation options.
Development, validation and measurement of pharmacokinetic and toxicokinetic assays across matrices and species using high-sensitivity immunoassay platforms and mitigation strategies for matrix interferences.
Custom development and validation of protein and nucleic acid biomarkers in multiple matrices and at single-cell level (flow cytometry, ELISpot, IHC, qPCR).
Tiered ADA testing (screening, confirmatory, neutralizing) including sample pre-treatment strategies and cell-based/non-cell-based neutralization assays for clinical sample analysis.
Independent lot release support for biologics, vaccines and small molecules including potency, protein analytics, physico‑chemical and stability-related tests performed under GMP requirements.
Custom potency assays, ADCC/ADCP/CDC, reporter-gene assays, whole blood and T‑cell cytotoxicity assays using primary cells, cell lines and 3D systems, with automation options.
Development, validation and measurement of pharmacokinetic and toxicokinetic assays across matrices and species using high-sensitivity immunoassay platforms and mitigation strategies for matrix interferences.
Custom development and validation of protein and nucleic acid biomarkers in multiple matrices and at single-cell level (flow cytometry, ELISpot, IHC, qPCR).
Expertise Areas
- Bioanalytical assay development and validation
- Immunogenicity assessment and ADA testing
- Cell-based bioassays and functional immunology
- Pharmacokinetics / Toxicokinetics analysis
Key Technologies
- Automated microfluidic nanoliter-scale immunoassays
- Electrochemiluminescence (ECL) multiplex immunoassays
- Time‑resolved fluorescence (TRF) and TR‑FRET detection
- Proximity homogeneous (Alpha) assays
News & Updates
The company lists achievement of GMP certification in its newsletter archive.
The company lists achievement of GMP certification in its newsletter archive.